Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria
Yun Mi Choi (Choi YM), Hyuk-Sang Kwon (Kwon HS), Kyung Mook Choi (Choi KM), Won-Young Lee (Lee WY), Eun-Gyoung Hong (Hong EG)
Endocrinol Metab. 2019;34(4):398-405.   Published online 2019 Dec 23     DOI: https://doi.org/10.3803/EnM.2019.34.4.398
Citations to this article as recorded by Crossref logo
The effects of beraprost sodium on renal function and cardiometabolic profile in patients with diabetes mellitus: a systematic review and meta-analysis of clinical trials
Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Kamran Hessami, Mojtaba Shabani-Borujeni, Mahnaz Hosseini-Bensenjan, Shahla Rezaei, Mohammad Jalali, Pedram Keshavarz, Fariba Ahmadizar
International Urology and Nephrology.2022; 54(1): 111.     CrossRef
Thrombocytopenia in COVID‑19 and vaccine‑induced thrombotic thrombocytopenia
Styliani Geronikolou, Işil Takan, Athanasia Pavlopoulou, Marina Mantzourani, George Chrousos
International Journal of Molecular Medicine.2022;[Epub]     CrossRef
The Role of Platelets in Diabetic Kidney Disease
Ukhti Jamil Rustiasari, Joris J. Roelofs
International Journal of Molecular Sciences.2022; 23(15): 8270.     CrossRef
Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171.     CrossRef